These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34305855)

  • 1. Inhibition of SARS CoV Envelope Protein by Flavonoids and Classical Viroporin Inhibitors.
    Breitinger U; Ali NKM; Sticht H; Breitinger HG
    Front Microbiol; 2021; 12():692423. PubMed ID: 34305855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2.
    Breitinger U; Sedky CA; Sticht H; Breitinger HG
    Virol J; 2023 Jul; 20(1):142. PubMed ID: 37422646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites.
    Fam MS; Sedky CA; Turky NO; Breitinger HG; Breitinger U
    Sci Rep; 2023 Apr; 13(1):5328. PubMed ID: 37005439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels.
    Breitinger U; Farag NS; Ali NKM; Ahmed M; El-Azizi MA; Breitinger HG
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33709903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.
    Toft-Bertelsen TL; Jeppesen MG; Tzortzini E; Xue K; Giller K; Becker S; Mujezinovic A; Bentzen BH; B Andreas L; Kolocouris A; Kledal TN; Rosenkilde MM
    Commun Biol; 2021 Dec; 4(1):1347. PubMed ID: 34853399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH.
    Cabrera-Garcia D; Bekdash R; Abbott GW; Yazawa M; Harrison NL
    J Physiol; 2021 Jun; 599(11):2851-2868. PubMed ID: 33709461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsecond molecular dynamics simulations revealed the inhibitory potency of amiloride analogs against SARS-CoV-2 E viroporin.
    Jaber AA; Chowdhury ZM; Bhattacharjee A; Mourin M; Keya CA; Bhuyan ZA
    Genomics Inform; 2021 Dec; 19(4):e48. PubMed ID: 35172476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.
    Breitinger U; Farag NS; Ali NKM; Breitinger HA
    Biophys J; 2016 Jun; 110(11):2419-2429. PubMed ID: 27276260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viroporins: Structure, function, and their role in the life cycle of SARS-CoV-2.
    Breitinger U; Farag NS; Sticht H; Breitinger HG
    Int J Biochem Cell Biol; 2022 Apr; 145():106185. PubMed ID: 35219876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor.
    Dey D; Borkotoky S; Banerjee M
    Comput Biol Med; 2020 Dec; 127():104063. PubMed ID: 33126128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II.
    Takano T; Nakano K; Doki T; Hohdatsu T
    Arch Virol; 2015 May; 160(5):1163-70. PubMed ID: 25701212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome.
    Chen IY; Moriyama M; Chang MF; Ichinohe T
    Front Microbiol; 2019; 10():50. PubMed ID: 30761102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The antiviral targeting potential of viroporins].
    Sund JD; Bollerup S; Glamann JB; Vinten CA; Jensen LR; Toft-Bethelsen TL; Bentzen BH; Kledal TN; Weis N; Rosenkilde M
    Ugeskr Laeger; 2022 Jun; 184(24):. PubMed ID: 35703076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexamethylene amiloride binds the SARS-CoV-2 envelope protein at the protein-lipid interface.
    Somberg NH; Medeiros-Silva J; Jo H; Wang J; DeGrado WF; Hong M
    Protein Sci; 2023 Oct; 32(10):e4755. PubMed ID: 37632140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.
    Jalily PH; Eldstrom J; Miller SC; Kwan DC; Tai SS; Chou D; Niikura M; Tietjen I; Fedida D
    Mol Pharmacol; 2016 Aug; 90(2):80-95. PubMed ID: 27193582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 infection alkalinizes the ERGIC and lysosomes through the viroporin activity of the viral envelope protein.
    Wang WA; Carreras-Sureda A; Demaurex N
    J Cell Sci; 2023 Mar; 136(6):. PubMed ID: 36807531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of Coronavirus and SARS-CoV-2.
    Malik YA
    Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of SARS-CoV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality.
    Rizwan T; Kothidar A; Meghwani H; Sharma V; Shobhawat R; Saini R; Vaishnav HK; Singh V; Pratap M; Sihag H; Kumar S; Dey JK; Dey SK
    J Biomol Struct Dyn; 2022; 40(20):10454-10469. PubMed ID: 34229570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Viroporin E Induces Ca
    López-Vázquez S; Villalobos C; Núñez L
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and inhibition of the SARS coronavirus envelope protein ion channel.
    Pervushin K; Tan E; Parthasarathy K; Lin X; Jiang FL; Yu D; Vararattanavech A; Soong TW; Liu DX; Torres J
    PLoS Pathog; 2009 Jul; 5(7):e1000511. PubMed ID: 19593379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.